Abstract
Implementing mechanisms for rewarding those who introduce innovative medicinal products requires a definition of 'rewardable innovation'. Here, we propose a definition of innovation with respect to medicinal products, accompanied by a ranking of the importance of different types of innovativeness, with the aim of providing a basis for rewarding such innovation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Innovation as a value in healthcare priority-setting: the UK experience
Social Justice Research Open Access 15 April 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ferner, R. E., Hughes, D. A. & Aronson, J. K. NICE and new: appraising innovation. BMJ 340, b5493 (2010).
Office of Fair Trading. Annexe L: Evaluation of options for reform to the PPRS. Office of Fair Trading website [online], (2007).
Kennedy, I. Appraising the value of innovation and other benefits. A short study for NICE. NICE website [online], (2009).
Aronson, J. K. Something new every day: defining innovation and innovativeness in drug therapy. J. Ambul. Care Manage. 31, 65–68 (2008).
Hughes, D. A. Value-based pricing: incentive for innovation or zero net benefit? Pharmacoeconomics 29, 731–735 (2011).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
J.K.A. is President Emeritus of the British Pharmacological Society, and a member of the Technology Appraisal Committee of the UK National Institute for Health and Clinical Excellence (NICE). R.E.F. is an NHS member of the NICE Appeal Panel. D.A.H. is a member of the Welsh Medicines Partnership. However, the opinions expressed here are not necessarily shared by other members of those organizations or the organizations themselves.
Supplementary information
Supplementary table 1
Features relevant to a definition of rewardable innovation and their inclusion in previous definitions (PDF 159 kb)
Supplementary table 2
The usefulness of therapeutic innovations from different perspectives (PDF 123 kb)
Supplementary table 3
Innovative features of a selection of beta-blockers (PDF 132 kb)
Supplementary table 4
Varieties of innovativeness ranked by degree (adapted from reference 1) (PDF 149 kb)
Rights and permissions
About this article
Cite this article
Aronson, J., Ferner, R. & Hughes, D. Defining rewardable innovation in drug therapy. Nat Rev Drug Discov 11, 253–254 (2012). https://doi.org/10.1038/nrd3715
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3715
This article is cited by
-
Newly approved cancer drugs in China — innovation and clinical benefit
Nature Reviews Clinical Oncology (2023)
-
Do current radical innovation measures actually measure radical drug innovation?
Scientometrics (2021)
-
Innovation as a value in healthcare priority-setting: the UK experience
Social Justice Research (2019)
-
Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006–2015: a cohort study
European Journal of Clinical Pharmacology (2016)
-
The most transformative drugs of the past 25 years: a survey of physicians
Nature Reviews Drug Discovery (2013)